CRA was retained by the petitioner in an IPR proceeding at the Patent Trial and Appeal Board (PTAB) to determine whether there was evidence of commercial success for certain pre-operative skin sterilization products. CRA’s team also conducted analyses demonstrating that the commercial performance of the product did not change following the issuance of the challenged patent. The PTAB found all challenged claims unpatentable and credited the testimony provided by Dr. Sean Sheridan.
Patent Damages: Recent Trends in Daubert Decisions
In this Insights, we update the Daubert Decision trends in last year’s Insights with 2021 data.[1] Daubert Decision trends are based on our review of available...